Company reaffirms commitment to reduce the global burden of HPV-related diseases, including certain cancers
Acquisition broadens oncology pipeline with a portfolio of novel T-cell engagers including HPN328 (MK-6070), an investigational delta-like ligand 3 (DLL3) targeting T-cell engager
Investigational cell therapy bemdaneprocel continues to be well tolerated with no major safety issues in all 12 participants in low and high dose cohorts through 18 months
The acquisition will build on AstraZeneca’s expertise in respiratory syncytial virus
This Phase III clinical trial is a randomized, double-blind, placebo-controlled, multicenter clinical trial in China to evaluate the safety and efficacy of ASC40
GC1130A has previously achieved notable milestones by securing both RPDD and ODD from the U.S. FDA in January 2023
SyntheticGestalt will develop a pre-trained AI model to discover synthesizable drug-like hit candidates
Argo will receive upfront payments of US$ 185 million from Novartis and is eligible to receive potential option and milestone payments as well as tiered royalties on commercial sales.
Acquisition includes HPN328, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager being evaluated in certain patients with small cell lung cancer and neuroendocrine tumors
Base4's drug discovery platform allows its collaborators to evaluate billions of novel small molecules to identify and progress RNA-modulators for important diseases
Subscribe To Our Newsletter & Stay Updated
